Lenvatinib

Lenvatinib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Hepatocellular Cancer、Squamous-Cell Non-Small Cell Lung Cancer、Recurrent Endometrial Cancer、Advanced Solid Tumor。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Lenvatinib 研究

• Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

  早期 I 期招募中美国NCT05553782

• A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

  I 期 / II 期招募中中国NCT06682780

• Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

  I 期招募中美国NCT05603910

• Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma

  II 期招募中中国NCT05954897

• Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

  II 期招募中中国NCT06406634

• Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC

  III 期招募中中国NCT06041477

• Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.

  IV 期招募中意大利NCT06903312

• Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

  II 期招募中中国NCT06482086

• Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy

  II 期招募中德国NCT05903833

• Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

  II 期招募中美国NCT05319015

• Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

  II 期招募中美国NCT04865887

• HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC

  不适用招募中中国NCT06632093

• Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer

  I 期 / II 期招募中中国NCT07636798

• Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

  II 期招募中中国NCT04803318

• Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer

  II 期招募中中国NCT07704177

• Merck IIT: RRP Pembro and Lenvatinib

  II 期招募中美国NCT04645602

• Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

  III 期招募中中国NCT05823311

• Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

  II 期招募中美国NCT06266338

• Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

  II 期招募中美国NCT05746208

• The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma

  不适用招募中中国NCT06609850

• A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

  III 期招募中中国NCT06371157

• Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)

  II 期招募中英国NCT05185739

• A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation

  III 期招募中RussiaNCT07809256

• Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites

  I 期 / II 期招募中South KoreaNCT07149090

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。